UroGen Expands Oncology Pipeline Through IntraGel Deal
PRINCETON, New Jersey, August 20, 2026 UroGen Pharma Ltd. announced a strategic collaboration and investment agreement with IntraGel Therapeutics,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PRINCETON, New Jersey, August 20, 2026 UroGen Pharma Ltd. announced a strategic collaboration and investment agreement with IntraGel Therapeutics,...
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
